Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ancey C, Corbi P, Froger J, Delwail A, Wijdenes J,Gascan H,Potreau D,Lecron JC (2002) Secretion of IL-6, IL-11 and LIF by human cardiomyocytes in primary culture. Cytokine 18:199–205
Ancey C, Menet E, Corbi P, Fredj S, Garcia M, Rucker-Martin C, Bescond J, Morel F,Wijdenes J, Lecron JC, Potreau D (2003) Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation. Cardiovasc Res 59:78–85
Antonicelli R, Olivieri F,Bonafe M,Cavallone L, Spazzafumo L,Marchegiani F, Cardelli M, Recanatini A, Testarmata P, Boemi M, Parati G, Franceschi C (2005) The interleukin-6–174 G→C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients. Int J Cardiol 103:266–271
Aoyama T, Takimoto Y, Pennica D, Inoue R, Shinoda E, Hattori R, Yui Y, Sasayama S (2000) Augmented expression of cardiotrophin-1 and its receptor component, gp130, in both left and right ventricles after myocardial infarction in the rat. J Mol Cell Cardiol 32:1821–1830
Asai S, Saito Y, Kuwahara K, Mizuno Y, Yoshimura M, Higashikubo C, Tsuji T, Kishimoto I, Harada M, Hamanaka I, Takahashi N, Yasue H, Nakao K (2000) The heart is a source of circulating cardiotrophin- 1 in humans. Biochem Biophys Res Commun 279:320–323
Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK, Nordoy I, Aass H, Espevik T, Simonsen S, Froland SS, Gullestad L (1999) Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83:376–382
Bader A, Al-Dubai H,Weitzer G (2000) Leukemia inhibitory factor modulates cardiogenesis in embryoid bodies in opposite fashions. Circ Res 86:787–794
Baines CP,Molkentin JD (2005) STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 38:47–62
Bamber B, Reife RA, Haugen HS, Clegg CH (1998) Oncostatin M stimulates excessive extracellular matrix accumulation in a transgenic mouse model of connective tissue disease. J Mol Med 76:61–69
Beckles DL,Mascareno E, Siddiqui MA (2006) Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. Vascul Pharmacol 45:350–357
Benigni F, Sacco S, Pennica D, Ghezzi P (1996) Cardiotrophin-1 inhibits tumor necrosis factor production in the heart and serum of lipopolysaccharidetreated mice and in vitro in mouse blood cells. Am J Pathol 149:1847–1850
Berry MF, Pirolli TJ, Jayasankar V, Morine KJ, Moise MA, Fisher O, Gardner TJ, Patterson PH, Woo YJ (2004) Targeted overexpression of leukemia inhibitory factor to preserve myocardium in a rat model of postinfarction heart failure. J Thorac Cardiovasc Surg 128:866–875
Betz UA, Bloch W, van den Broek M, Yoshida K,Taga T,Kishimoto T,Addicks K,Rajewsky K,Muller W (1998) Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic,immunological,hepatic, and pulmonary defects. J Exp Med 188:1955–1965
Bhat GJ, Abraham ST, Baker KM (1996) Angiotensin II interferes with interleukin 6-induced Stat3 signaling by a pathway involving mitogen-activated protein kinase kinase 1. J Biol Chem 271:22447–22452
Birks EJ, Latif N, Owen V, Bowles C, Felkin LE,Mullen AJ, Khaghani A, Barton PJ,Polak JM,Pepper JR,Banner NR, Yacoub MH (2001) Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation 104:I233–240
Booz GW, Day JN, Baker KM (2002) Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 34:1443–1453
Bossowska A, Kiersnowska-Rogowska B, Bossowski A, Galar B, Sowinski P (2003) Cytokines in patients with ischaemic heart disease or myocardial infarction. Kardiol Pol 59:105–114
Brar BK, Stephanou A, Liao Z, O’Leary RM, Pennica D, Yellon DM, Latchman DS (2001) Cardiotrophin-1 can protect cardiac myocytes from injury when added both prior to simulated ischaemia and at reoxygenation. Cardiovasc Res 51:265–274
Brar BK, Stephanou A, Pennica D, Latchman DS (2001) CT-1 mediated cardioprotection against ischaemic reoxygenation injury is mediated by PI3 kinase, Akt and MEK1/2 pathways. Cytokine 16:93–96
Briest W, Rassler B, Deten A, Leicht M, Morwinski R, Neichel D, Wallukat G, Ziegelhoffer T, Zimmer HG (2003) Norepinephrine- induced interleukin-6 increase in rat hearts: differential signal transduction in myocytes and nonmyocytes. Pflugers Arch 446:437–446
Buzas K,Megyeri K,Hogye M, Csanady M, Bogats G,Mandi Y (2004) Comparative study of the roles of cytokines and apoptosis in dilated and hypertrophic cardiomyopathies. Eur Cytokine Netw 15:53–59
Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE, Jr., Kuriyan J (1998) Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93:827–839
Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY (2003) Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 33:941–948
Craig R,Wagner M, McCardle T, Craig AG, Glembotski CC (2001) The cytoprotective effects of the glycoprotein 130 receptor-coupled cytokine, cardiotrophin- 1, require activation of NFkappa B. J Biol Chem 276:37621–37629
David M, Chen HE, Goelz S, Larner AC, Neel BG (1995) Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domaincontaining tyrosine phosphatase SHPTP1.Mol Cell Biol 15:7050–7058
Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB,Hunt G,Wu WJ,Tan W, Bolli R (2004) IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res 64:61–71
Ebelt H, Jungblut M, Zhang Y, Kubin T, Kostin S, Technau A, Oustanina S, Niebrugge S, Lehmann J, Werdan K, Braun T (2007) Cellular cardiomyoplasty: improvement of left ventricular function correlates with the release of cardioactive cytokines. Stem Cells 25:236–244
Eiken HG,Oie E,Damas JK,Yndestad A, Bjerkeli V, Aass H, Simonsen S, Geiran OR, Tonnessen T, Christensen G, Froland SS, Gullestad L, Attramadal H, Aukrust P (2001) Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur J Clin Invest 31:389–397
El-Adawi H, Deng L, Tramontano A, Smith S, Mascareno E, Ganguly K, Castillo R, El-Sherif N (2003) The functional role of the JAK-STAT pathway in post-infarction remodeling.Cardiovasc Res 57:129–138
Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR, FitzGerald O, Bresnihan B,Veale DJ (2006) Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 54:3152–3162
Fischer P, Lehmann U, Sobota RM, Schmitz J, Niemand C, Linnemann S, Haan S, Behrmann I, Yoshimura A, Johnston JA,Muller-Newen G,Heinrich PC, Schaper F (2004) The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. Biochem J 378:449–460
Florholmen G,Aas V, Rustan AC, Lunde PK, Straumann N, Eid H, Odegaard A, Dishington H, Andersson KB, Christensen G (2004) Leukemia inhibitory factor reduces contractile function and induces alterations in energy metabolism in isolated cardiomyocytes. J Mol Cell Cardiol 37:1183–1193
Foshay K,Rodriguez G,Hoel B,Narayan J, Gallicano GI (2005) JAK2/STAT3 directs cardiomyogenesis within murine embryonic stem cells in vitro. Stem Cells 23:530–543
Freed DH, Borowiec AM,Angelovska T, Dixon IM (2003) Induction of protein synthesis in cardiac fibroblasts by cardiotrophin- 1: integration of multiple signaling pathways. Cardiovasc Res 60:365–375
Freed DH,Cunnington RH,Dangerfield AL, Sutton JS, Dixon IM (2005) Emerging evidence for the role of cardiotrophin- 1 in cardiac repair in the infarcted heart. Cardiovasc Res 65:782–792
Freed DH, Moon MC, Borowiec AM, Jones SC, Zahradka P, Dixon IM (2003) Cardiotrophin-1: expression in experimental myocardial infarction and potential role in post-MI wound healing. Mol Cell Biochem 254:247–256
Fuchs M, Hilfiker A, Kaminski K, Hilfiker- Kleiner D, Guener Z, Klein G, Podewski E, Schieffer B, Rose-John S, Drexler H (2003) Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. Faseb J 17:2118–2120
Funamoto M, Fujio Y, Kunisada K, Negoro S, Tone E, Osugi T, Hirota H, Izumi M, Yoshizaki K, Walsh K, Kishimoto T, Yamauchi-Takihara K (2000) Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem 275:10561–10566
Gaussin V, Van de Putte T, Mishina Y, Hanks MC, Zwijsen A, Huylebroeck D, Behringer RR, Schneider MD (2002) Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3.Proc Natl Acad Sci U S A 99:2878–2883
Gonzalez A, Lopez B, Martin-Raymondi D, Lozano E, Varo N, Barba J, Serrano M, Diez J (2005) Usefulness of plasma cardiotrophin- 1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens 23:2297–2304
Grenier A, Combaux D, Chastre J, Gougerot-Pocidalo MA, Gibert C, Dehoux M, Chollet-Martin S (2001) Oncostatin M production by blood and alveolar neutrophils during acute lung injury. Lab Invest 81:133–141
Gritman K, Van Winkle DM, Lorentz CU,Pennica D,Habecker BA (2006) The lack of cardiotrophin-1 alters expression of interleukin-6 and leukemia inhibitory factor mRNA but does not impair cardiac injury response. Cytokine 36:9–16
Gwechenberger M,Moertl D, Pacher R, Huelsmann M (2004) Oncostatin-M in myocardial ischemia/reperfusion injury may regulate tissue repair. Croat Med J 45:149–157
Gwechenberger M, Pacher R, Berger R, Zorn G, Moser P, Stanek B, Huelsmann M (2005) Comparison of soluble glycoprotein 130 and cardiac natriuretic peptides as long-term predictors of heart failure progression. J Heart Lung Transplant 24:2190–2195
Haspel RL, Darnell JE, Jr. (1999) A nuclear protein tyrosine phosphatase is required for the inactivation of STAT1. Proc Natl Acad Sci USA 96:10188–10193
Hattori R, Maulik N, Otani H, Zhu L, Cordis G, Engelman RM, Siddiqui MA, Das DK (2001) Role of STAT3 in ischemic preconditioning. J Mol Cell Cardiol 33:1929–1936
Heinrich PC, Behrmann I,Haan S,Hermanns HM,Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)–6- type cytokine signalling and its regulation. Biochem J 374:1–20
Heinrich PC, Behrmann I, Muller- Newen G,Schaper F,Graeve L (1998) Interleukin- 6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334 (Pt 2):297–314
Heinrich PC, Bode J, Decker M, Graeve L,Martens A,Muller-Newen G, Pflanz S, Schaper F, Schmitz J (2001) Termination and modulation of IL-6-type cytokine signaling. Adv Exp Med Biol 495:153–160
Hilfiker-Kleiner D,Hilfiker A,Drexler H (2005) Many good reasons to have STAT3 in the heart. Pharmacol Ther 107:131–137
Hilfiker-Kleiner D,Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, Hillmer A, Schmiedl A, Ding Z, Podewski E, Poli V, Schneider MD, Schulz R,Park JK,Wollert KC,Drexler H (2004) Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition,and heart protection from ischemic injury. Circ Res 95:187–195
Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R,Hilfiker A, Drexler H (2007) A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum Cardiomyopathy. Cell 128:589–600
Hilfiker-Kleiner D,Limbourg A,Drexler H (2005) STAT3-mediated activation of myocardial capillary growth. Trends Cardiovasc Med 15:152–157
Hirano T, Nakajima K, Hibi M (1997) Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev 8:241–252
Hiraoka E, Kawashima S, Takahashi T, Rikitake Y, Hirase T, Yokoyama M (2003) PI 3-kinase-Akt-p70 S6 kinase in hypertrophic responses to leukemia inhibitory factor in cardiac myocytes. Kobe J Med Sci 49:25–37
Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross J, Jr., Muller W, Chien KR (1999) Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97:189–198
Hirota H, Izumi M, Hamaguchi T, Sugiyama S, Murakami E, Kunisada K, Fujio Y, Oshima Y, Nakaoka Y, Yamauchi- Takihara K (2004) Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels 19:237–241
Hirota H,Yoshida K, Kishimoto T, Taga T (1995) Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 92:4862–4866
Hishinuma S, Funamoto M, Fujio Y,Kunisada K, Yamauchi-Takihara K (1999) Hypoxic stress induces cardiotrophin-1 expression in cardiac myocytes. Biochem Biophys Res Commun 264:436–440
Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ (2001) The interleukin- 6–174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 22:2243–2252
Iemitsu M, Maeda S, Miyauchi T, Matsuda M, Tanaka H (2005) Gene expression profiling of exercise-induced cardiac hypertrophy in rats. Acta Physiol Scand 185:259–270
Ihn H, Tamaki K (2000) Oncostatin M stimulates the growth of dermal fibroblasts via a mitogen-activated protein kinase-dependent pathway. J Immunol 165:2149–2155
Ishikawa M, Saito Y, Miyamoto Y, Harada M, Kuwahara K, Ogawa E, Nakagawa O,Hamanaka I, Kajiyama N, Takahashi N, Masuda I, Hashimoto T, Sakai O, Hosoya T, Nakao K (1999) A heart-specific increase in cardiotrophin- 1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. J Hypertens 17:807–816
Jacoby JJ, Kalinowski A, Liu MG, Zhang SS, Gao Q, Chai GX, Ji L, Iwamoto Y,Li E, Schneider M, Russell KS, Fu XY (2003) Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci U S A 100:12929–12934
Jamshidi Y,Zourlidou A,Carroll CJ,Sinclair J, Latchman DS (2004) Signaltransduction pathways involved in the hypertrophic effect of hsp56 in neonatal cardiomyocytes. J Mol Cell Cardiol 36:381–392
Jin H,Yang R, Keller GA, Ryan A, Ko A, Finkle D, Swanson TA, Li W, Pennica D, Wood WI, Paoni NF (1996) In vivo effects of cardiotrophin-1. Cytokine 8:920–926
Jougasaki M, Leskinen H, Larsen AM, Cataliotti A, Chen HH, Burnett JC, Jr. (2003) Leukemia inhibitory factor is augmented in the heart in experimental heart failure. Eur J Heart Fail 5:137–145
Jougasaki M, Tachibana I, Luchner A, Leskinen H, Redfield MM, Burnett JC, Jr. (2000) Augmented cardiac cardiotrophin- 1 in experimental congestive heart failure. Circulation 101:14–17
Kaneko K, Kanda T, Yokoyama T, Nakazato Y, Iwasaki T, Kobayashi I, Nagai R (1997) Expression of interleukin- 6 in the ventricles and coronary arteries of patients with myocardial infarction. Res Commun Mol Pathol Pharmacol 97:3–12
Kato T, Sano M, Miyoshi S, Sato T, Hakuno D, Ishida H, Kinoshita- Nakazawa H, Fukuda K,Ogawa S (2000) Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats. Circ Res 87:937–945
Keller ET,Wanagat J, Ershler WB (1996) Molecular and cellular biology of interleukin- 6 and its receptor. Front Biosci 1:d340–357
Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL (2006) Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction. J Card Fail 12:635–640
Kishimoto T (1994) Signal transduction through homo- or heterodimers of gp130. Stem Cells 12(Suppl 1):37–44; discussion 44–35
Kodama H, Fukuda K, Pan J,Makino S, Baba A, Hori S, Ogawa S (1997) Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 81:656–663
Kodama H, Fukuda K, Pan J, Sano M, Takahashi T, Kato T,Makino S,Manabe T, Murata M, Ogawa S (2000) Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130- mediated cardiac hypertrophy. Am J Physiol Heart Circ Physiol 279: H1635–1644
Kunisada K,Hirota H,Fujio Y,Matsui H, Tani Y, Yamauchi-Takihara K, Kishimoto T (1996) Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes. Circulation 94:2626–2632
Kunisada K, Negoro S, Tone E, Funamoto M,Osugi T,Yamada S,Okabe M, Kishimoto T, Yamauchi-Takihara K (2000) Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin- induced cardiomyopathy. Proc Natl Acad Sci USA 97:315–319
Kunisada K, Tone E, Fujio Y, Matsui H, Yamauchi-Takihara K, Kishimoto T (1998) Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 98:346–352
Kurdi M, Randon J, Cerutti C, Bricca G (2005) Increased expression of IL-6 and LIF in the hypertrophied left ventricle of TGR(mRen2)27 and SHR rats. Mol Cell Biochem 269:95–101
Kuwahara K, Saito Y, Kishimoto I, Miyamoto Y, Harada M, Ogawa E, Hamanaka I, Kajiyama N, Takahashi N, Izumi T, Kawakami R, Nakao K (2000) Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes. J Mol Cardiol 32:1385–1394
Lafontant PJ, Burns AR, Donnachie E, Haudek SB, Smith CW, Entman ML (2006) Oncostatin M differentially regulates CXC chemokines in mouse cardiac fibroblasts. Am J Physiol Cell Physiol 291:C18–26
Latchman DS (2000) Cardiotrophin-1: a novel cytokine and its effects in the heart and other tissues. Pharmacol Ther 85:29–37
Lehmann U, Schmitz J,Weissenbach M, Sobota RM, Hortner M, Friederichs K, Behrmann I, Tsiaris W, Sasaki A, Schneider-Mergener J, Yoshimura A, Neel BG,Heinrich PC, Schaper F (2003) SHP2 and SOCS3 contribute to Tyr-759- dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem 278:661–671
Li YJ, Cui W, Tian ZJ,Hao YM, Du J, Liu F, Zhang H, Zu XG, Liu SY, Xie RQ,Yang XH, Wu YZ, Chen L, An W (2004) Crosstalk between ERK1/2 and STAT3 in the modulation of cardiomyocyte hypertrophy induced by cardiotrophin- 1. Chin Med J (Engl) 117:1135–1142
Lopez B, Gonzalez A, Lasarte JJ, Sarobe P, Borras F, Diaz A, Barba J, Tomas L, Lozano E,Serrano M,Varo N,Beloqui O, Fortuno MA, Diez J (2005) Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens 23:625–632
Lopez N, Diez J, Fortuno MA (2005) Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. Cytokine 30:282–292
Lopez N,Diez J,Fortuno MA (2006) Differential hypertrophic effects of cardiotrophin- 1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. J Mol Cell Cardiol 41:902–913
Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T,Kinoshita M (2000) High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36:1587–1593
Mascareno E, Beckles DL, Siddiqui MA (2005) Janus kinase-2 signaling mediates apoptosis in rat cardiomyocytes. Vascul Pharmacol 43:327–335
Masson S, Latini R, Bevilacqua M,Vago T, Sessa F, Torri M, Anesini A, Salio M, Pasotti E,Agnello D, Santoro L, Catania A, Ghezzi P, Moccetti T, Maggioni AP (1998) Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res 37:213–217
Matsui H,Fujio Y,Kunisada K,Hirota H, Yamauchi-Takihara K (1996) Leukemia inhibitory factor induces a hypertrophic response mediated by gp130 in murine cardiac myocytes. Res Commun Mol Pathol Pharmacol 93:149–162
Matsushita K, Iwanaga S,Oda T,Kimura K, Shimada M, Sano M, Umezawa A, Hata J, Ogawa S (2005) Interleukin- 6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis. Lab Invest 85:1210–1223
Meldrum DR, Meng X, Sheridan BC, McIntyre RC, Jr., Harken AH, Banerjee A (1998) Tissue-specific protein kinase C isoforms differentially mediate macrophage TNFalpha and IL-1beta production. Shock 9:256–260
Miyata S, Takemura G, Kawase Y, Li Y, Okada H, Maruyama R, Ushikoshi H, Esaki M, Kanamori H, Li L, Misao Y, Tezuka A, Toya-Oka T, Minatoguchi S, Fujiwara T, Fujiwara H (2006) Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor.Am J Pathol 168:386–397
Murakami M, Hibi M, Nakagawa N, Nakagawa T,Yasukawa K,Yamanishi K, Taga T, Kishimoto T (1993) IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260:1808–1810
Murata M, Fukuda K, Ishida H, Miyoshi S, Koura T, Kodama H, Nakazawa HK, Ogawa S (1999) Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, enhances L-type Ca2+ current and (Ca2+)i transient in cardiomyocytes. J Mol Cell Cardiol 31:237–245
Nakaoka Y, Nishida K, Fujio Y, Izumi M,Terai K,Oshima Y,Sugiyama S,Matsuda S, Koyasu S, Yamauchi-Takihara K,Hirano T,Kawase I,Hirota H (2003) Activation of gp130 transduces hypertrophic signal through interaction of scaffolding/docking protein Gab1 with tyrosine phosphatase SHP2 in cardiomyocytes. Circ Res 93:221–229
Negoro S, Kunisada K, Fujio Y, Funamoto M, Darville MI, Eizirik DL, Osugi T, Izumi M, Oshima Y, Nakaoka Y, Hirota H, Kishimoto T, Yamauchi- Takihara K (2001) Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 104:979–981
Nemoto S, Sheng Z, Lin A (1998) Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy. Mol Cell Biol 18:3518–3526
Nian M, Lee P, Khaper N, Liu P (2004) Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94:1543–1553
Oh H, Fujio Y,Kunisada K, et al. (1998) Activation of phosphatidylinositol 3- kinase through glycoprotein 130 induces protein kinase B and p70, S6 kinase phosphorylation in cardiac myocytes. J Biol Chem 273:9703–9710
Olivier C, Auguste P, Chabbert M, Lelievre E, Chevalier S, Gascan H (2000) Identification of a gp130 cytokine receptor critical site involved in oncostatin M response. J Biol Chem 275:5648–5656
Omura T, Yoshiyama M, Ishikura F, Kobayashi H, Takeuchi K, Beppu S, Yoshikawa J (2001) Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. J Mol Cell Cardiol 33:307–316
Orus J, Roig E, Perez-Villa F, Pare C, Azqueta M, Filella X, Heras M, Sanz G (2000) Prognostic value of serum cytokines in patients with congestive heart failure. J Heart Lung Transplant 19:419–425
Oshima Y, Fujio Y,Nakanishi T, Itoh N, Yamamoto Y, Negoro S, Tanaka K, Kishimoto T,Kawase I,Azuma J (2005) STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc Res 65:428–435
Osugi T, Oshima Y, Fujio Y, Funamoto M,Yamashita A,Negoro S,Kunisada K, Izumi M, Nakaoka Y, Hirota H, Okabe M, Yamauchi-Takihara K, Kawase I, Kishimoto T (2002) Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem 277:6676–6681
Pan J, Fukuda K, Kodama H, Sano M, Takahashi T,Makino S,Kato T,Manabe T,Hori S, Ogawa S (1998) Involvement of gp130-mediated signaling in pressure overload-induced activation of the JAK/STAT pathway in rodent heart. Heart Vessels 13:199–208
Pemberton CJ, Raudsepp SD, Yandle TG, Cameron VA, Richards AM (2005) Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res 68:109–117
Pennica D,Wood WI, Chien KR (1996) Cardiotrophin-1: a multifunctional cytokine that signals via LIF receptorgp 130 dependent pathways. Cytokine Growth Factor Rev 7:81–91
Petersen AM, Pedersen BK (2006) The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 57 (Suppl 10):43–51
Plun-Favreau H, Perret D, Diveu C, Froger J, Chevalier S, Lelievre E, Gascan H, Chabbert M (2003) Leukemia inhibitory factor (LIF), cardiotrophin- 1, and oncostatin M share structural binding determinants in the immunoglobulin- like domain of LIF receptor. J Biol Chem 278:27169–27179
Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC, Drexler H (2003) Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 107:798–802
Pourtau J,Mirshahi F,Li H,Muraine M, Vincent L, Tedgui A,Vannier JP, Soria J,Vasse M, Soria C (1999) Cyclooxygenase- 2 activity is necessary for the angiogenic properties of oncostatin M FEBS Lett 459:453–457
Railson J, Lawrence K, Stephanou A, Brar B, Pennica D, Latchman D (2000) Cardiotrophin-1 reduces stress-induced heat shock protein production in cardiac myocytes. Cytokine 12:1741–1744
Railson JE, Liao Z, Brar BK, Buddle JC, Pennica D, Stephanou A,Latchman DS (2002) Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes. Cytokine 17:243–253
Raju SV, Zheng M, Schuleri KH, Phan AC, Bedja D, Saraiva RM, Yiginer O, Vandegaer K, Gabrielson KL, O’Donnell C P, Berkowitz DE, Barouch LA, Hare JM (2006) Activation of the cardiac ciliary neurotrophic factor receptor reverses left ventricular hypertrophy in leptin-deficient and leptinresistant obesity. Proc Natl Acad Sci USA 103:4222–4227
Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P (2003) C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 21:1787–1803
Roig E, Orus J, Pare C, Azqueta M, Filella X, Perez-Villa F, Heras M, Sanz G (1998) Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 82:688–690, A688
Roy S, Khanna S, Kuhn DE, Rink C, Williams WT, Zweier JL, Sen CK (2006) Transcriptome analysis of the ischemia-reperfused remodeling myocardium: temporal changes in inflammation and extracellular matrix. Physiol Genomics 25:364–374
Saito M, Yoshida K, Hibi M, Taga T, Kishimoto T (1992) Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J Immunol 148:4066–4071
Sano M, Fukuda K, Kodama H, Pan J, Saito M, Matsuzaki J, Takahashi T, Makino S, Kato T, Ogawa S (2000) Interleukin- 6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem 275:29717–29723
Sano M, Fukuda K, Sato T, Kawaguchi H, Suematsu M, Matsuda S, Koyasu S, Matsui H, Yamauchi-Takihara K, Harada M, Saito Y, Ogawa S (2001) ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ Res 89:661–669
Sarkar S,Vellaichamy E, Young D, Sen S (2004) Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: role of myocytes. Am J Physiol Heart Circ Physiol 287:H107–117
Scaffidi AK,Mutsaers SE,Moodley YP, McAnulty RJ, Laurent GJ, Thompson PJ, Knight DA (2002) Oncostatin M stimulates proliferation,induces collagen production and inhibits apoptosis of human lung fibroblasts. Br J Pharmacol 136:793–801
Schmidt BM, Schmieder RE (2005) Cardiotrophin: its importance as a pathogenetic factor and as a measure of left ventricular hypertrophy. J Hypertens 23:2151–2153
Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR (1997) Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen- activated protein kinase-dependent pathway.Divergence from downstream CT-1 signals for myocardial cell hypertrophy. J Biol Chem 272:5783–5791
Sheng Z, Pennica D,Wood WI, Chien KR (1996) Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development 122:419–428
Smith RM,Suleman N,Lacerda L,Opie LH, Akira S, Chien KR, Sack MN (2004) Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res 63:611–616
Somasundaram R, Ruehl M, Schaefer B, Schmid M, Ackermann R, Riecken EO, Zeitz M, Schuppan D (2002) Interstitial collagens I, III, and VI sequester and modulate the multifunctional cytokine oncostatin MJ Biol Chem 277: 3242–3246
Stephanou A, Brar B, Heads R, Knight RD,Marber MS, Pennica D, Latchman DS (1998) Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli. J Mol Cell Cardiol 30:849–855
Strand K, Murray J, Aziz S, Ishida A, Rahman S, Patel Y, Cardona C, Hammond WP, Savidge G, Wijelath ES (2000) Induction of the urokinase plasminogen activator system by oncostatin M promotes endothelial migration. J Cell Biochem 79:239–248
Takahashi N, Saito Y, Kuwahara K, Harada M, Tanimoto K, Nakagawa Y, Kawakami R, Nakanishi M, Yasuno S, Usami S,Yoshimura A,Nakao K (2005) Hypertrophic responses to cardiotrophin- 1 are not mediated by STAT3, but via a MEK5-ERK5 pathway in cultured cardiomyocytes. J Mol Cell Cardiol 38:185–192
Takeda K,Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S (1997) Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality.Proc Natl Acad Sci USA 94:3801–3804
Takimoto Y, Aoyama T, Iwanaga Y, Izumi T, Kihara Y, Pennica D, Sasayama S (2002) Increased expression of cardiotrophin-1 during ventricular remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol 282:H896–901
Talwar S, Squire IB, Downie PF, O’Brien RJ,Davies JE, Ng LL (2000) Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. Clin Sci (Lond) 99:83–88
Tanaka T, Kanda T, McManus BM, Kanai H, Akiyama H, Sekiguchi K, Yokoyama T, Kurabayashi M (2001) Overexpression of interleukin-6 aggravates viral myocarditis: impaired increase in tumor necrosis factor-alpha. J Mol Cell Cardiol 33:1627–1635
Tanimoto K, Saito Y, Hamanaka I, Kuwahara K, Harada M, Takahashi N, Kawakami R, Nakagawa Y, Nakanishi M, Adachi Y, Shirakami G, Fukuda K, Yoshimura A, Nakao K (2005) SOCS1/ JAB likely mediates the protective effect of cardiotrophin-1 against lipopolysaccharide- induced left ventricular dysfunction in vivo. Circ J 69:1412–1417
Tian ZJ,Cui W,Li YJ,Hao YM, Du J,Liu F, Zhang H, Zu XG, Liu SY, Chen L, An W (2004) Different contributions of STAT3,ERK1/2,and PI3-K signaling to cardiomyocyte hypertrophy by cardiotrophin- 1. Acta Pharmacol Sin 25:1157–1164
Toh R,Kawashima S,Kawai M, Sakoda T, Ueyama T, Satomi-Kobayashi S, Hirayama S, Yokoyama M (2004) Transplantation of cardiotrophin-1- expressing myoblasts to the left ventricular wall alleviates the transition from compensatory hypertrophy to congestive heart failure in Dahl saltsensitive hypertensive rats. J Am Coll Cardiol 43:2337–2347
Tone E, Kunisada K, Fujio Y, Matsui H, Negoro S, Oh H, Kishimoto T, Yamauchi-Takihara K (1998) Angiotensin II interferes with leukemia inhibitory factor-induced STAT3 activation in cardiac myocytes. Biochem Biophys Res Commun 253:147–150
Tone E, Kunisada K, Kumanogoh A, Negoro S,Funamoto M,Osugi T,Kishimoto T, Yamauchi-Takihara K (2000) gp130-Dependent signalling pathway is not enhanced in gp130 transgenic heart after LIF stimulation. Cytokine 12:1512–1518
Tonnessen T, Florholmen G, Henriksen UL, Christensen G (2003) Cardiopulmonary alterations in mRNA expression for interleukin-1beta, the interleukin-6 superfamily and CXCchemokines during development of postischaemic heart failure in the rat. Clin Physiol Funct Imaging 23:263–268
Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL (1996) Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27:1201–1206
Trial J, Rossen RD, Rubio J, Knowlton AA (2004) Inflammation and ischemia: macrophages activated by fibronectin fragments enhance the survival of injured cardiac myocytes. Exp Biol Med (Maywood) 229:538–545
Tsuruda T, Jougasaki M, Boerrigter G, Huntley BK, Chen HH, D’Assoro AB, Lee SC, Larsen AM, Cataliotti A, Burnett JC, Jr. (2002) Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/ leukemia inhibitory factor receptor and the endothelin type A receptor. Circ Res 90:128–134
Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M, Kinoshita M (1998) Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31:391–398
Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Fujii M, Matsumoto T, Yamamoto T, Wang X, Asai S, Tsuji T, Tanaka H, Saito Y,Kuwahara K,Nakao K, Kinoshita M (2001) Relationship between plasma level of cardiotrophin- 1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol 38:1485–1490
Uozumi H,Hiroi Y, Zou Y,Takimoto E, Toko H,Niu P,Shimoyama M,Yazaki Y, Nagai R, Komuro I (2001) gp130 plays a critical role in pressure overload-induced cardiac hypertrophy. J Biol Chem 276:23115–23119
Vasse M, Pourtau J, Trochon V, Muraine M,Vannier JP,Lu H, Soria J, Soria C (1999) Oncostatin M induces angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol 19:1835–1842
Villegas S,Villarreal FJ, Dillmann WH (2000) Leukemia Inhibitory Factor and Interleukin-6 downregulate sarcoplasmic reticulum Ca2+ ATPase (SERCA2) in cardiac myocytes. Basic Res Cardiol 95:47–54
Vona-Davis L, Zhu X, Yu AK, McFadden DW (2003) Modulation of interleukin- 6 in cardiac myoblasts during endotoxemia. J Surg Res 112:91–96
Wang F, Seta Y, Baumgarten G, Engel DJ, Sivasubramanian N, Mann DL (2001) Functional significance of hemodynamic overload-induced expression of leukemia-inhibitory factor in the adult mammalian heart. Circulation 103:1296–1302
Wang F, Trial J, Diwan A, Gao F, Birdsall H, Entman M,Hornsby P, Sivasubramaniam N, Mann D (2002) Regulation of cardiac fibroblast cellular function by leukemia inhibitory factor. J Mol Cell Cardiol 34:1309–1316
Wang M,Markel T, Crisostomo P,Herring C, Meldrum KK, Lillemoe KD, Meldrum DR (2007) Deficiency of TNFR1 protects myocardium through SOCS3 and IL-6, but not p38 MAPK or IL-1 beta. Am J Physiol Heart Circ Physiol 292(4):H1694–H1699
Watters DJ,Hendry IA (1987) Purification of a ciliary neurotrophic factor from bovine heart. J Neurochem 49:705–713
Weiss TW, Kvakan H, Kaun C, Zorn G, Speidl WS, Pfaffenberger S,Maurer G, Huber K, Wojta J (2005) The gp130 ligand oncostatin M regulates tissue inhibitor of metalloproteinases-1 through ERK1/2 and p38 in human adult cardiac myocytes and in human adult cardiac fibroblasts: a possible role for the gp130/gp130 ligand system in the modulation of extracellular matrix degradation in the human heart. J Mol Cell Cardiol 39:545–551
Weiss TW, Speidl WS,Kaun C, Rega G, Springer C, Macfelda K, Losert UM, Grant SL, Marro ML, Rhodes AD, Fuernkranz A, Bialy J, Ullrich R,Holzmann P, Pacher R,Maurer G,Huber K, Wojta J (2003) Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes. Cardiovasc Res 59:628–638
Wijelath ES, Carlsen B, Cole T, Chen J, Kothari S, Hammond WP (1997) Oncostatin M induces basic fibroblast growth factor expression in endothelial cells and promotes endothelial cell proliferation, migration and spindle morphology. J Cell Sci 110(Pt 7):871–879
Wollert KC, Chien KR (1997) Cardiotrophin- 1 and the role of gp130-dependent signaling pathways in cardiac growth and development. J Mol Med 75:492–501
Wollert KC, Taga T, Saito M, Narazaki M, Kishimoto T, Glembotski CC, Vernallis AB, Heath JK, Pennica D,Wood WI, Chien KR (1996) Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/ leukemia inhibitory factor receptordependent pathways. J Biol Chem 271:9535–9545
Xu J, Ren JF,Mugelli A, Belardinelli L, Keith Jr JC, Jr., Pelleg A (2002) Age-dependent atrial remodeling induced by recombinant human interleukin-11: implications for atrial flutter/fibrillation. J Cardiovasc Pharmacol 39: 435–440
Yajima T, Yasukawa H, Jeon ES, Xiong D, Dorner A, Iwatate M, Nara M, Zhou H, Summers-Torres D, Hoshijima M, Chien KR,Yoshimura A,Knowlton KU (2006) Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling. Circulation 114:2364–2373
Yamauchi-Takihara K, Kishimoto T (2000) Cytokines and their receptors in cardiovascular diseases–role of gp130 signalling pathway in cardiac myocyte growth and maintenance. Int J Exp Pathol 81:1–16
Yamaura G, Turoczi T, Yamamoto F, Siddqui MA,Maulik N, Das DK (2003) STAT signaling in ischemic heart: a role of STAT5A in ischemic preconditioning. Am J Physiol Heart Circ Physiol 285:H476–482
Yasukawa H,Hoshijima M,Gu Y,Nakamura T, Pradervand S, Hanada T, Hanakawa Y, Yoshimura A, Ross J, Jr., Chien KR (2001) Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J Clin Invest 108:1459–1467
Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN,Yoshimura A (1999) The JAKbinding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. Embo J 18:1309–1320
Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T,Aki D,Hanada T, Takeda K, Akira S, Hoshijima M, Hirano T, Chien KR,Yoshimura A (2003) IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages.Nat Immunol 4:551–556
Yellon DM, Baxter GF (1999) Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury? Trends Cardiovasc Med 9:245–249
Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H,Hirata M,Yamagami T,Nakahata T, et al. (1996) Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 93:407–411
Zhang X, Guo A, Yu J, Possemato A, Chen Y, Zheng W, Polakiewicz RD, Kinzler KW, Vogelstein B, Velculescu VE, John Wang Z (2007) Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci USA 104:4060–4064
Zolk O, Engmann S,Munzel F, Krajcik R (2005) Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue. Am J Physiol Endocrinol Metab 288:E1214–1221
Zolk O, Ng LL, O’Brien RJ,Weyand M, Eschenhagen T (2002) Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation 106:1442–1446